Buscar
Congreso SOLACI
HomeACC.15.Day 3

Day 3

Ver Categoría
Day 3

TOTAL: The thromboaspiration provides no benefit in primary angioplasty

In patients undergoing ST segment elevation myocardial infarction (STEMI) who received primary angioplasty, the strategy of manual...
solaci -
Ver más
Day 3

MATRIX: The radial access reduces events, bivalirudin with mixed results

Two separate works are part of the MATRIX study investigating strategies to reduce bleeding and mortality in...
solaci -
Ver más
Day 3

IMPROVE-IT: The combination simvastatin / ezetimibe reduces post SCA events

This work included 18144 patients from 39 countries that were admitted pursuing an acute coronary syndrome (with...
solaci -
Ver más
Day 3

DANAMI3: Primary Angioplasty to culprit vessel versus multivessel guided by FFR

The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel...
solaci -
Ver más
Day 3

BEST: Similar mortality among angioplasty with DES (everolimus) and surgery

This observational registry compared the results of myocardial revascularization with angioplasty performed using everolimus-eluting stents in patients...
solaci -
Ver más
Day 3

After 80: The octogenarian patients with acute coronary syndrome benefit from an aggressive strategy

This work published simultaneously in The New England Journal of Medicine showed that patients over eighty years...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Evolution of Small Balloon-Expandable Valves

Dr. Carlos Fava - 0
Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

solaci - 0
Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

Noticias Institucionales

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad